Table 1.
Short‐chain fatty acids in clinical trials.
| Drug | Conditions | Recruitment | NCT number | Phases |
|---|---|---|---|---|
| Valproic acid & fludarabine | Chronic lymphocytic leukemia | Terminated | NCT00524667 | Phase 2 |
| Azacitidine, valproic acid | Advanced cancers | Completed | NCT00496444 | Phase 1 |
| Temozolomide + valproic acid | Brain metastases | Terminated | NCT00437957 | Phase 1 |
| 5‐Azacytidine + valproic acid + ATRA | Myelodysplastic syndromes | Completed | NCT00439673 | Phase 2 |
| 5 azacytidine + valproic acid + retinoic acid | AML, MDS | Completed | NCT00339196 | Phase 2 |
| Enfuvirtide + valproic acid | HIV infections | Terminated | NCT00312546 | Phase 1 |
| Valproic acid | HTLV‐I‐associated myelopathy | Terminated | NCT00519181 | N/A |
| Karenitecin + valproic acid | Malignant melanoma | Terminated | NCT00358319 | Phase 1, 2 |
| Valproic acid | ALPS|hypersplenism|lymphadenopathy | Completed | NCT00605657 | Phase 1, 2 |
| Raltegravir + valproic acid | HIV infections | Terminated | NCT00614458 | Phase 2 |
| Hydralazine + magnesium valproate | Cervical cancer | Completed | NCT00404326 | Phase 2 |
| Hydralazine + magnesium valproate | Locally advanced breast cancer | Terminated | NCT00395655 | Phase 2 |
| Hydralazine + magnesium valproate | Refractory solid tumors | Completed | NCT00404508 | Phase 2 |
| Sodium phenylbutyrate | Huntington's disease | Completed | NCT00212316 | Phase 2 |
| Sodium phenylbutyrate | Amyotrophic lateral sclerosis | Completed | NCT00107770 | Phase 1, 2 |
| Pivanex | Leukemia, lymphocytic, lymphoma, small lymphocytic | Terminated | NCT00083473 | Phase 2 |
| Pivanex | Malignant melanoma | Terminated | NCT00087477 | Phase 1, 2 |
| Pivanex/docetaxel | Carcinoma, non‐small‐cell lung | Completed | NCT00073385 | Phase 2 |